Federal Register / Vol. 69, No. 205 / Monday, October 25, 2004 / Notices 62295

and field usage of steel roof decks, 

composite floor decks and noncomposite steel floor decks.

Dorothy B. Fountain, 

Deputy Director of Operations, Antitrust 

Division.

[FR Doc. 04–23779 Filed 10–22–04; 8:45 am] 

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Steel Door Institute 

Notice if hereby given that, on 

September 17, 2004, pursuant to section 

6(a) of the National Cooperative 

Research and Production Act of 1993, 

15 U.S.C. 4301 et seq. (‘‘the Act’’), the 

Steel Door Institute (‘‘SDI’’) has filed 

written notifications simultaneously 

with the Attorney General and the 

Federal Trade Commission disclosing 

(1) the name and principal place of 

business of the standards development 

organization and (2) the nature and 

scope of its standards development 

activities. The notifications were filed 

for the purpose of invoking the Act’s 

provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Pursuant to section 6(b) of the Act, the 

name and principal place of business of 

the standards development organization 

is: Steel Door Institute, Cleveland, OH. 

The nature and scope of SDI’s standards 

development activities are: SDI acts as 

secretariat for the ANSI A250 

Committee, which develops standards 

for dimension, nomenclature, 

construction, performance, testing, and 

installation of steel doors and frames 

used in residential and commercial 

construction.

Dorothy B. Fountain, 

Deputy Director of Operations, Antitrust 

Division.

[FR Doc. 04–23778 Filed 10–22–04; 8:45 am] 

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances Notice of Application 

Pursuant to 21 CFR 1301.33(a), this is 

notice that on April 20, 2004, Cody 

Laboratories, Inc., 301 Yellowstone 

Avenue, Cody, Wyoming 82414, made 

application by renewal to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed:

Drug Schedule 

Amphetamine (1100) ................ II 

Methamphetamine (1105) ........ II 

Amobarbital (2125) ................... II 

Pentobarbital (2270) ................. II 

Secobarbital (2315) .................. II 

Cocaine (9041) ......................... II 

Oxycodone (9143) .................... II 

Dihydromorphine (9145) ........... II 

Hydromorphone (9150) ............ II 

Diphenoxylate (9170) ............... II 

Meperidine (9230) .................... II 

Oxymorphone (9652) ................ II 

Sufentanil (9740) ...................... II 

Fentanyl (9801) ........................ II 

The company plans to manufacture 

bulk materials for distribution to its 

customers. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative (CCD) 

and must be filed no later than 

December 27, 2004.

Dated: October 18, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–23767 Filed 10–22–04; 8:45 am] 

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to 21 CFR 1301.33(a), this is 

notice that on July 13, 2004, National 

Center for Natural Products Research—

NIDA MProject, University of 

Mississippi, 135 Coy Waller Complex, 

University, Mississippi 38677, made 

application by renewal to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed:

Drug Schedule 

Marihuana (7360) ..................... I 

Drug Schedule 

Tetrahydrocannabinols (7370) .. I 

The company plans to cultivate 

marihuana for the National Institute of 

Drug Abuse for research approved by 

the Department of Health and Human 

Services. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, United 

States Department of Justice, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative (CCD) 

and must be filed no later than 

December 27, 2004.

Dated: October 18, 2004. 

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–23766 Filed 10–22–04; 8:45 am] 

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances Notice of Application 

Pursuant to 21 CFR 1301.33(a), this is 

notice that on July 13, 2004, National 

Center for Development of Natural 

Products, The University of Mississippi, 

135 Coy Waller Lab Complex, 

University, Mississippi 38677, made 

application by renewal to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed:

Drug Schedule 

Marihuana (7360) ..................... I 

Tetrahydrocannabinols (7370) .. I 

The company plans to bulk 

manufacture for product development. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 C.F.R. 1301.33(a). 

Any such comments or objections 

may be addressed, in quintuplicate, to 

the Deputy Assistant Administrator, 

Office of Diversion Control, Drug